Form 8-K

0001171843-24-006945.txt : 20241213 0001171843-24-006945.hdr.sgml : 20241213 20241213164034 ACCESSION NUMBER: 0001171843-24-006945 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241213 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241213 DATE AS OF CHANGE: 20241213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Edesa Biotech, Inc. CENTRAL INDEX KEY: 0001540159 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37619 FILM NUMBER: 241548979 BUSINESS ADDRESS: STREET 1: 100 SPY COURT CITY: MARKHAM STATE: A6 ZIP: L3R 5H6 BUSINESS PHONE: (905) 475-1234 MAIL ADDRESS: STREET 1: 100 SPY COURT CITY: MARKHAM STATE: A6 ZIP: L3R 5H6 FORMER COMPANY: FORMER CONFORMED NAME: Stellar Biotechnologies, Inc. DATE OF NAME CHANGE: 20120120 8-K 1 f8k_121324.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 13, 2024

_______________________________

EDESA BIOTECH, INC.

(Exact name of registrant as specified in its charter)

_______________________________

British Columbia, Canada	001-37619	N/A
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Spy Court

Markham, Ontario L3R 5H6

(Address of Principal Executive Offices) (Zip Code)

(289) 800-9600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	EDSA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On December 13, 2024, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended September 30, 2024 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release issued by Edesa Biotech, Inc. dated December 13, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EDESA BIOTECH, INC.


Date: December 13, 2024	By:	/s/ Stephen Lemieux
		Stephen Lemieux
		Chief Financial Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Edesa Biotech Reports Fiscal Year 2024 Results

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business.

During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project for the same asset that is supported by the Government of Canada. The company said that the goal is to maximize synergies between the two government-funded projects. For its anti-CXCL10 program, Edesa intends to manufacture EB06 and submit related data to the U.S. Food and Drug Administration as part of an investigational new drug (IND) application. The manufacturing of clinical-grade drug batches and initiation of the patient enrollment is subject to funding. Edesa anticipates topline results for this Phase 2 study could be available within as few as 12 to 18 months following regulatory clearance in the U.S. The study is currently approved in Canada.

“This year, Edesa maintained its momentum despite the headwinds in the drug development sector, and we once again validated our TLR4 technology with a third competitive government award,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “I have maintained my strategic support financially and I believe that our team can continue to advance and expand our development pipeline and partnerships.”

Edesa's Chief Financial Officer Stephen Lemieux reported that financial results for the fiscal year benefited from prudent use of working capital and effective financial management, including a more than 20% decrease in operating expenses. “Following the end of the fiscal year, we strengthened our balance sheet, and with two governments now funding the advancement of our anti-TLR4 technology, we have improved our position for future financing, potential strategic arrangements as well as other opportunities to advance our pipeline.”

Financial Results for the Fiscal Year Ended September 30, 2024

Total operating expenses decreased by $2.2 million to $7.0 million for the year ended September 30, 2024 compared to $9.2 million for the prior year:

Research and development expenses decreased by $1.9 million to $2.9 million for the year ended September 30, 2024 compared to $4.8 million for the prior year primarily due to decreased external research expenses related to the company’s completed dermatitis study and a reduction in labor costs and noncash share-based compensation, which were partially offset by an increase in expenses related to manufacturing of paridiprubart.
General and administrative expenses decreased by $0.3 million to $4.1 million for year ended September 30, 2024 compared to $4.4 million for the prior year primarily due to a decrease in noncash share-based compensation, which was partially offset by an increase salaries and related costs.

Total other income was unchanged at $0.8 million for the years ended September 30, 2024 and September 30, 2023 as a $0.1 million increase in reimbursement funding from the Canadian government's Strategic Innovation Fund was offset by a $0.1 million decrease in interest income.

For the year ended September 30, 2024, Edesa reported a net loss of $6.2 million, or $1.93 per common share, compared to a net loss of $8.4 million, or $2.93 per common share, for the year ended September 30, 2023.

Working Capital

At September 30, 2024, Edesa had cash and cash equivalents of $1.0 million and negative working capital of $0.2 million. Subsequent to the fiscal year end, the company received $1.5 million in gross proceeds under a securities purchase agreement with an entity affiliated with Edesa’s Chief Executive Officer and Founder, and $0.6 million in net proceeds, after deducting sales agent commissions, from common shares sold under an at-the-market offering program.

Calendar

Edesa management plans to participate in one-on-one meetings during JP Morgan week, which begins on January 13, 2025, in San Francisco, California. Attendees interested in meeting with management can request meetings through the conference organizers or by contacting Edesa directly at investors@edesabiotech.com.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company’s most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. In addition to EB05, Edesa is preparing an investigational new drug application (IND) in the United States for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis. Sign up for news alerts. Connect with us on X and LinkedIn.

Edesa Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: Edesa’s ability to pivot the in-house development of its anti-TLR4 drug candidate; the company’s plans to amend its contribution agreement with the Government of Canada; the company’s goal to maximize synergies between two government-funded projects; Edesa plans to manufacture EB06 and submit related data to the FDA as part of an IND application; the company’s plans to manufacture clinical-grade drug and initiate patient enrollment; the company’s plans to finance clinical and manufacturing activities; the company’s estimate that topline results for its Phase 2 vitiligo study could be available within as few as 12 to 18 months following regulatory clearance; the company’s belief that in 2024 it maintained its momentum despite the headwinds in the drug development sector and once again validated its TLR4 technology with a third competitive government award; the company’s belief that its team can continue to advance and expand its development pipeline and partnerships; the company’s belief that its fiscal year financial results benefited from prudent use of working capital and effective financial management; the company’s belief that with two governments funding the advancement of its anti-TLR4 technology, it has improved its position for future financing, potential strategic arrangements and alternatives as well as other opportunities to advance its pipeline; and the company's timing and plans regarding its clinical studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.


Consolidated Statements of Operations

	Years Ended
	September 30, 2024			September 30, 2023

Expenses:
Research and development	$	2,881,967		$	4,794,549
General and administrative		4,132,777			4,428,209

Loss from operations		(7,014,744	)		(9,222,758	)

Other Income (Loss):
Reimbursement grant income		698,277			581,039
Other income (loss)		147,222			268,104

Income tax expense		800			800

Net loss		(6,170,045	)		(8,374,415	)

Exchange differences on translation		(27,965	)		(1,046	)

Net comprehensive loss	$	(6,198,010	)	$	(8,375,461	)

Weighted average number of common shares		3,197,423			2,858,929

Loss per common share - basic and diluted	$	(1.93	)	$	(2.93	)


Consolidated Balance Sheets

	September 30, 2024		September 30, 2023

Assets:
Cash and cash equivalents	$	1,037,320	$	5,361,397
Other current assets		638,302		1,075,455
Non-current assets		2,138,360		2,453,585

Total Assets	$	3,813,982	$	8,890,437

Liabilities and shareholders' equity:
Current liabilities	$	1,832,827	$	1,821,864
Non-current liabilities		-		19,773
Shareholders' equity		1,981,155		7,048,800

Total liabilities and shareholders' equity	$	3,813,982	$	8,890,437


Consolidated Statements of Cash Flows

	Years Ended
	September 30, 2024			September 30, 2023

Cash flows from operating activities:
Net loss	$	(6,170,045	)	$	(8,374,415	)
Adjustments for non-cash items		708,775			1,429,928
Change in working capital items		571,065			308,004

Net cash used in operating activities		(4,890,205	)		(6,636,483	)

Net cash provided by financing activities		592,031			4,830,111

Effect of exchange rate changes on cash and cash equivalents		(25,903	)		76,850

Net change in cash and cash equivalents		(4,324,077	)		(1,729,522	)
Cash and cash equivalents, beginning of year		5,361,397			7,090,919

Cash and cash equivalents, end of year	$	1,037,320		$	5,361,397

Contact:
Gary Koppenjan
Edesa Biotech, Inc.
(289) 800-9600
investors@edesabiotech.com

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 13, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 13, 2024
Entity File Number	001-37619
Entity Registrant Name	EDESA BIOTECH, INC.
Entity Central Index Key	0001540159
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	100 Spy Court
Entity Address, City or Town	Markham
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	L3R 5H6
City Area Code	289
Local Phone Number	800-9600
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares
Trading Symbol	EDSA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_121324.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_121324.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_121324.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 21 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_121324.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_121324.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001171843-24-006945-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-006945-xbrl.zip M4$L#!!0 ( !"%C5FMFH9'+A< +FT + 97AH7SDY,2YH=&WM7?E2 M(\G1?P*_0YE=>R&B);IU( D8P@S'&'NN&-B8W3]+W26I=OIR'S#ZGO[+S*H^ M=($ 78 >?D>)!X+G.YWW^W(_S*[]?XD>#. MR7$B$U><7#A]'EU*5_K]XWWUT;$G$L[LP$^$G[S;2<3/9!]'.6+V@$>Q2-[= M2=\)[N**56O6=IB^P>>>>+?SX>+SQ;?3FR_?=HH1/ET3@>VJ:59;!Z95M=IF MIX$W[BM2NH$S9-V^';A!]&[GEQ[]#P@-69P,7:%HJ'!7]OU#%LG^(#F";^,D M"OS^R<4?_[YZ?W7#.IVJ=;RO/SS>#V?<;@-)(L+[>T!?=@6^K\3R_\0ALQKA MR/".B#E[+X-$V /V381!E,3L4L8V=]F?@D>L9M8:\$6E_I!1?H]EWL>3X)HR!P9"QZ+V&!)X/ ABTB@<'=/^MRW)_ M=-I2_B MN(JR91."/4\C9&=L,H,^R"00RMM <\FD7QD$((],%A[HD@4]FHK[B:SB@'T\'OUNLKZP:V(?!RKTDN) MSSA)P3&D?ROB1/9Y@D3Z<)4+5$2"@RWU?5"!M._3A/19"+?"L#&[D\F G=HI M2 8,-I214LJY!-,#\;#KH>]$@2?8[NFW\^N]*OL@;X4/X\F8!2%J*O5E,C2T M=<&GW(V! 2#:0>+XB$10)R0$C_MIC]N)$C.HZ2^@,]=O#+V ,1$PGP M;2+5S' UDJB-!UPO"ER75$ :ZI(2@0\4&8Q>U=) 0=D2[A(H$:#'%V,N#;=_ M'0 (L)JV<#M(75 U6,$MER[ONH(L51+W/6 17JP:SF6UF0>X.L"A7#>X0ZXB MT4]=9APT#_]P"&#."U XJ0<^ *X%+H8$8(##(!=3S/@S+;H$*ATPF2"-&F()@[D.8[ ^5+W,49^20%P@(W^"N)6MF_(Y' MCD'T6T?*1;X"BGZ6?PW@*]]@G\X-=C:0HL0M$1UD#@85<"Y\I-D:=$< \ADG(%Z:>" MX-"Y)17B/>)GB"]X;5EFH0P%&1;!/K@'>'8\D&%#3 K] T1B1QA-T;:"4$0J M0H#,A \A-M?79>XJ2*Q >?8F@]T=.@FX1A^^\;7-=;E+JH@'0B3:1-'L1D$S MAJ!TE\$ #:Q5F.$U#E7$Q<*&:5*R)>EI7\1+PT#EL"3?7DI@JD7C]PWX&M-* ME%)A<0:M5[8S06BO]_01: M&]7V/;3B6P_R*P <1V%)00RDWF"NRGD5!SG%66#6,5EG%&@.5NLHIK]=09%; M0&Z,*!OK>()"X'"_D]IDL."'$+Z &AOR,150?0!T'@_ A8")2I=H(;3V8PJS MX ,#"=3XX@Q%FM7ZB"(;56M$$X]28N-12N0C0#>W0'7F=)\\8\"W2.K4 M)Q,HZ:Y:DM<^V/Y,9R6 @0$Q:\8I4Q^J9( BD&N"4INT5V0ROK^2F?BXCF#& M<;Q"ZF6KB(3TNBD4Y^2+&113!,(I*;V1P'D!VA &KW/XO/*AK%!9WV6*((_0 M64AL=-ZR,C#U!8=*M 1F)%"7\SAZEE7E09=#=ILP-XB1%O;K00%3!H,!$5KJ M#+ 2M0])H3((8\34QH9H%X:GAJA-'V(>8*K/X#4+%-]UI#_3D7X"^D].DWND M,.!@B&CF: [T1OPOE9 14H1#9JP2ZA/0B+YRX/$< R\V"^%5V77:C6$TM!0- M>6,E]FCE"T6ED!B;820T (04:@-4P!:-!7> MCX2R396V HY!"$_ MB#U1'M2\C&.X#RXDARG; @!] *6)9@T$G51 -!7 IQ\" M4YN>R$I:+ @?,(DSU)[#HP>R@*RXR#) %D(21FD+P9FJK2CE\T4E\.'_D(M# M?@:$ &BK&/"?K^Q3$/6!8BAT?V20V 5GAY& N?] Q.!0,.D>4A.S3'8-EU]B M^036$$!= %2!)_@2*NW3!$M<(>+;OI94::%+C+GHM'Y*.$VSLL)&>&=7EV$L3 ME;R'H-MH578%<)!-7=1%,BZW[#!=+_6$(%N&FP_9)^'07>>4UJBJ$N4&%./61==\+&QM*2)[FPBESBUTG MW<1291:U;2RV"^@*]178I9MB0PPB!,C,HZ:IZEW401?MBC\IF9\H'M,PIY=P]/3O?*\DE ML.TTS!I!) 1P'$<6S9_Q1-:#Q"8K?4:T/-:J1*U.;U8J&)'80:/Z!.)1RC44 MS.QB GPEP+:7Y-!2(A2!,75Z/]N,F6L9AZH+%8<#HR2Y$?0D^=0T8R=*0Y@':T(M$A!U3 M,%T?6X-T9TKAY@_"E8_2_R&<*_\!H%;B@)P155#Y& 24S1!75-\_@-?'PCNA M5EU(!@2(2LYVB,6OLL!W=B\.WF%_@*YJ;I[_&*M!.\)WJ;N,[F ]? M[B#-HE?LVN(;.WL3#[)W'B[2T=@9 L(?8"@[6:-OAX1S"Y9)ADRA/Y:0P6$& M^I-4IU*RHOM5XKRH?0_',D9("%S,*S%;PA6;)Z_7'$WM!>2I&.E'1QL_B60W M5=WZT3QW%G),'YP6+1Y8L;AWM>)(0TE.Y6.7(R[/3\<6' !?RH#S@%3*\TU; M:2BM,$Q;6'A@=-4#+$:FX49['Y@VWI)K31\K,W&]4C1E>0)5FJ%AEHPL;9EB M.I'DFCV]&.:KK@ H;)'+#22ZJ4L-./23EQKFX >&G[?KC]?.U?6?;]IRD3O9 MRU]TW_YAFJ9VTN_IHH^B5;F+#L:!64W>1,(WN!30S5=@H'P;7 .,APJBIY&1]U:^L0I((8 *5H@HUS >$ M!XFE+K8IL,U'5@\ZFQWBLRP6BB"ZG;-^BMZ8"-*T%E4H(DPKD1_*(1'0P&*[ M> \FE$R QT@H*"*$#DO8H*WPX?$GA^9X1( T,7+C]AQ_21T3H8A@7L8K6#@'W4":;Q^U8-:^0#*4=3L.H7!W;1U+U)Y0? MZ^5KEJT,ZK473$A08F@?(WB/U9O*NDJ?@;W/2H MB,PMLD?;XF(CAS 6/ >&BU,NR[NNQ& D0-F@UBQS_!)6Z;&(.V!&NU=[#V@ M6"F$C7HA6DU7#(,)K"QQ3XEFX*(-0G[L2#M1NU.P/Q;;*;&F$$R5HB2TIX515(5 MB0-#P/NP6RDC54.Y_"ZKRA'J/8$KW !9KJ[&R9K5!C."[Q(('N]#^4F%Z7%" M#J^W_MU))QD<6J;YCR/6I1Y6Q8;4D(>Q.,S>L+^#@8%8(18='8U?Q+)W1PQJ MW"2"?YB+N3'HX]U.>V?V'D-VQ!@D&-2$S+[QI..X--0_?[$.S*/C_<0!LFG8 MA0V=%?1JBC, U2#+,HMJ'A7V)4?=4FT_3M "^"NS55^(Q#:5K@<$IS#Y2?2U M+H3[67/VF!5.VA>)Q!/(.O^O+Y&EGMH_7E ML3TALRWJ!3)67X/JWJ K8]-S/BU=Z(T=AY,6]P#)C]?-*A3\R &GR-'C/RLJ M,+>:$)=+;R%'*WUS-&L&QL95@9^%V.+W^Q7\^Y!9S:H9_D1J9NV=&I=:058M MIZHV0A3\=93-0F(X9.:8_\YO%[_.1*""D$Y.2&>$D$Z)$,4NTO$ :7,H+J.- MU8QVVS(Z!ZTYB+1R(JT1(JVI1#Y.6-/M>[ZY%^)**S**7S?'!AI&J],PFHW. M^C4^!3L6 PFS]^&-,_U@\'Z^P*<;WMP3+\/_&X95KQFMUFSW?P)YB_#\U8KV M5>BT831J;:-F3OCS2E6X:%:O+R8E*JIZ4@'W$C(?68@UFM@&**93G% M,G%LMV68%@2TQNQR[[E&GDVUMS;!O02%[':,6@TB2K.]:/GO3>FAN3R.W^T, MTK[T)UVQ_&79,>^]\&FC+,Q1OU!G^4IM=]]%M]W;EI.+30F_C6SE[^/*I-Y= M_Y+]+C.@@PZD />DA:#;K$YG6)B=2N0-\*3]2LXL/;^R]9%5D MEF\U6AAZMI:_7''7#MJ&9396;/F;%)DVDZJ%I2 Z^4CXS^Q1Q?%%HK=:8&<2 M:IOFMEWRXK5)6MRL1LDFX#%QVOI^:L$SP5TJ:_ZMH-J#D2UEM$Y MF(U"2X^T#\/4-F5Z/*I9$%H.5J[++>1M2,*$NY,C,8":$+?(8_HTKX,[08J; M=955U.?QC$7LKYF?B*7LK<%LK-,V3&ONC5.VUS0: M!];J]?NJE\6^"Q0^GE4$U^"I'WY*VV#QH,WR*3(ON53('+0.8-$R&A/[>K<= M[$5WL(UVLVUT:JM>O=FDM& SJ5KL?I?Q<\=8A75YC,_AXO9@Z:8 +$OK;"\A M?5EM!8=']'1F8]&V@%M4CK*BTJU&VEQ_Y79_6O'&0&ZS,K5]>J+R!,].U*=S MKN@QR\5JJ;:1MK,0JJ8^0'KP[ =(1QX=?:_/I+[&,ZE7^,#H= &M_RFSQ="U MO'RP]EH?K%P78ZM[L/*-(-6S4OE3.D+RODVP;TN**WZF\FS6&$WI:>7S,??(#M,:42[@5M&?7:[#[OXQ]D?/XCD^MZCG'98F\:]0/+J'=: M,WUDD?MD]>_9Z*-LU]?W>NI^\'K;J)M3=L7>6S1L.G?@<-AO;S:7; *? []R MOP&\I 7@)YI0S;#0B YFH]LB<.L5"[(&EEHWFNUE6^OC4I&_TCB1O>%S4Z2G M#+-HRI8FT&U+WD]->^I&VZH;G?;L9R[>U#KR8_9+BM01<+KF+/P[]GH/0:37ST@WN MM@>A;P]"WQZ$_CH86_=!Z.N.NYNU]9X@MH<0.W+@Y,AOQVV/M%O3;I[LU(L7 ML'EG;2>BSW&&QFH.R'[X"8CM\>A+-(C91WBL1OVSGWI?#!:<.MBST;^*B+\Q MC-UU!&\)(?95/%'9,MM&J[6\HW"VSU/JY9]&K6-T:@L_\7$DM[\5Y4K-E&>8ZCW/9GGJW((W6 1/-R>,[UWWRW7-\N;;]B8!%G>^" MX3^-U4^<3BO<7M=A>0WJU]?,=1Z6]^:R!2BO#NH'1J,]\33R]IBHUP0C^(N_ MTE&_]YK_+OIKA9)FIV:8=6M;:2Q7W #8==.PK(ECEK8GM[QT_+B@7U['-3J1 MG;$9X>\_J_=TR*8][Z.(;RNC+X[<;!H=W!Y6_/4"D1"KO M3'F?FV0,&ZXJ^ M]'VL*"!C& H>O>THD=651(#[Z^\YDFT,F$=2FCO; MF;:Q=7S>3TFY^64Q]#\>W[UJ#=[;[_I?F/FXD& M, -U&UNHG78*)7F\WEQ7BT*.2XY]7J]M$"8G 5J+#+A*N6R4_KCR_W G; I M+?! :1JX+/G(Y\&WW?AQ-0$=2I^O@>*;F$BUM(4:5KW5!VG@RY)=7 /5F: 7 M%E3'H%R)6L6YVL>'A4@^6.R"=9!GD)#]\;%_OP+7V? KT)*6-% C(:=4@PD1 MTT6A7"E4+E-("HJY:XC@N3@6SP?Q7!>J3HQGRSCKDN+RD*I$XQ[;4'=,$Q;@ MBTHU!I1LM!/M90E68\"9*HPI#1/@$55# Q@MK&&%=U+X3&5"FQ4$=PIE)R6B M*V:!ELMLOJ/%-2I*ZFT"\-("-6\FC'K-&\VUSYJ?0+?DNO#YIF2?;TIV=2B\ M)5%ZZ;/;W$@$ND&<?X*X^KT*?+ M!@E$P#[ &E\T$#>3]D?N>2PP/P) ;S8%#"X)Z!0_9;S1"8"A99N!=-3O!AY; M?&;+''&!%[;0?30/\G[].4>X=YOCB^>"4ZWGFF6(YHL:_*W?E-9P-\D&+>M6 M^*EN# 4HGP8CZJ.OK+AH35G@P5_]R:?C ]1KY5SS$R+8)&R>4_*"]S )^8PI MX D]M*%,Z@&TQ.23QL2XWSB8%\#CZV6G[!07RLM%JWH9 GN*3T.?Y4J H[2) MU#PK,9/VT>2E1L2\83AB/EEC1MO)(_?PQ8@S20QK+#-.V]W/Z_K>_!A9R\0? M@EZ$ESQ"5I3ZCFK6! ^M%9P*F#+^R_"'BTOX;9I&M(5WS8L[X> (I M=BA\P(8>6J ^'P<-XD+@,)D(9-B[S)"P; 3\VNL^=>[(X*GUU!GG>D\T?[MU;OUPYI/WSYTAT,N@^]M^'FTG#S.U43Z!2U M@/IT5VP72:5\4:NODO+C3*H9#331 AH9%SM- MXE2)D,2YR'MG-T-9:HH1T1.&RS/)-8:Z?'*N ML=(AW3X+A=0D'S\S"EF4*4W8,^ CTBPS[ZQA\]*^+L@#%%/@<>+1Y1+PL""7 MX8*/IJAV;*T]Y(L.,,I<-AU"*^%4SPD6[5-XYHO\]%49-G3ONW<]+MM8O[U;/E5 ?SY [_R7<6%#P7)4"W MD0GGA"JB0N9B"^<1'A"N%0%?!R^29R>RE:9#G\58TN4SYE5:K=.9%LD[GXWB M5[FH)M_FRJ!DYOLJI"[N#L3/(?6\Z!FHR9C4,Y.:N]2/F08-H5&UM\%+M?HN MLO_+XW?+25(AAC-O@WEC*D,IGJ/A;3W,K"-U U=(B%PS]PXT1%K; K>%=]"O M8,C[B%E*34A;^+/ID---ISHG;1I0#]YK+TO^6I;\6:[VBB#YQ'T&:Y 2#@E2 MP_D"9N&K2V=KG-O%^?=9[I^%P@'NG^BB&TTXKK'.'E%P.K)_-KDO%)J]4LO* M4-+R13YZC%T@OHW78!5[@,HER;^@<"F/V_(& ;_F86>;VCR21EM,IUSA-AU! MJQ*KB]=BZQ;[Q4&1=&"P%4M@>5W/I">*9RF-E4P2,28CCP+F1)^T/ ]F!D6B M6+EMMWJMNQ8AH.WOR*"VB&0TOJ]Q_HC%Z+]['C#G4!1NC;\^""?Q#PX)-MEKOF%RF\3.MW.4 ?2J$+_QC2*3&3ET(@9$P@QRJ[GFI7KK4)RMMNN]P+RL)'YJ'IUA9-7N5RH7VXG_!]GSE7/^5X! M'I^%QDB!X?@<&CC7GV$O1*"AIR! VIXH E@2F]6W-*]#$B=G"#ZH3Y@/A4Q6/2J=I;5&U[PMQO0[& 4?'X\H,M;O2&!UC] MTOW[H0$:"9HIE8:0%D/)L?X#!V3(?#%'P7$QWO$G(^ZC5W %+J(94/-P %9\ M.O,U#9B8*7])%)1>-5J:+Z,/Q!!XI7$;@0NIV6$&>$#9P3)>&PD?B.-WF*HY MM@JJ<=P,L%?>K1[OQ\P![[)=&,S!/= \LX5:7_JDTJU7 3 L]#WN_4O$(E/SP[SA@6]N]ICJY2,R9?8)3:_\\H55:HY=WCC!+! M[IHB4PGMR12GMRG<*;*VDC()M3C,VI4V[A=55I#.%E)SQ&2KZ?&[8AF%]U"% M?/$FQ'&%//;U^KM#)VVYYA->4K"[W.Z$N-"ZJ=?L-;R(L4KU&,8D-3WV8#F% MYCBO7K4%\C)]71_!5B_:W37J8G%<@"?-)QS>K-SMV#3U4A\ >'#"K7L>6=DD M59-M0"R=RM 8/)UI+J#1A90 (@RB ^?-?&/IO5S]KV(ULKLU>YK/2]S;'[1. MS]X3A/X1+&YM.H/QMS=*8DW'*=.>6JRDN$(74A[]:VLO9* %N!KNW3!-[N_; M:X*M959[!([YM0/?CC%*?I5BKG%S>AKBJ/ V:;8;>%A&($DN80+$60G OD$D M,+,_NC'(P%A$ \)BCL>68S?BF"KBL1$/[ &)[8W+%V3[E'!U.%@E>3R!N_I@ M^N,8F)NCE1"/5G!8M26M,BQ4,G!EG3@F2+&\K;Y+H2V^8-+^'O5V=JCJM2V) MW5.+L5J/B1SF4#=RO:<;>1-==$=[G >W9#(]D6]-TQ/P,^9#\0<_"X1I!6:* M&2C@*YK9\8HD-^V!O>Z$*C:T_"42GW,@C88(V!Q=3#*8PN$[\%X:N#AS4-<< M1"$PWD_UJ/24G=:]77U(-4^3/B3MED62*#[<>45GYX9S9C6K)?=L-J[6I+"' M=,P*0\GHM\*0@?A@4.K/Z5(=NVFTAAA3%6Z0=#6;VLV;F-[.*T06RPV8303C M)GY(*L5RI4CZ3,U\;?9:'T(FHRX6E$P^)?IO"_ '7(!0C3!LBYA!+6P^!&3K M=/V<=#RF*/G(A6;NY!P/>HHDCY;Z^:?K2J7\(8HB\^1\.(-4!]V^1RC8'+>% M)7@0DZL6A%A/)>V<)DA2.S?W,[=W)EUU8V-L<[MJ+]Y@;G>J)XL!&-AZ!RN$CER0,??2^#=TRYDH<(N#:8["-Z-'.O MD6@=[BAN;BBQU[C98O)GO>X4)QHDP^1T4Z*'!X#7<9E-]'$MKT?I'N(QJU!X M)F%L597BBNFCI'?*M1\D8EO 6$H>H>(#P]#@4M><6MY13>T=A#QR[F&"Q=8' M$@PFLJ[YG1*"OU1"O.@B6]8V4#KS[+UG_'=H8@805%3/Y(N.H/9=[!ET?^VU MGK[V._O[Z/4KE;:G_6O&992'CRV5&Z^X_USJY)?.7I].<0)"\I S M=UTB_(YMYUK]WPK?]AEFLZ1*T+*P<,("2; MNE?ZP"!NI,SOIZTFQ54&SE>NZVMJ[2WR0%#K1F;V::D?[]K MP DD) JTY;8)KS>9!P]4Z69%$LOF$P]1$4D8R;2I??XX']YN+F[ M\]#UU:>/H8Z>:$80,(1>>D_&Y N,R[*35PL>%, M_.V#!_/Y'%>S#GJ W*P5=](S;*?71-.M,LRR$W@FM"$BZN!CLR6TP9]Q/=F! MLE[H90UE#AK3/9RFT225SQ@F '\Q<\!"^RDA^1:<$+VN1)N)#E@KJI#2$6YA:9FBE0+@2BVG"!*LR3NLG0#ZZE5%A M6X1A10GQ/K@E46@:?Q=7U3A75 .O:F$%@8;80(Z0(L*C@@_C[$KII30!MU2[ MQ7.[Y"=-4+6[%M8'2T^S+.=V+U2Q)T63I0=^\-TG^@.=3< F#F&53VRN:N'W M%Z/)ZR2(B@Y4#C8_B,B<*L/ JZT=7E?.C*7_:*5!-H_V$'Z#CCE9#^T8*)2_ M8ZLKJ_^6/8*-AO;8==X[-7J[3=+NMCD1\.Y(:-[WCXT0^I;*('%P")VZ!^H; M;"6C2NH$Q;[YCN?;D!]<^+-@LM'QKM(A1>R685@1CC>BB".W45]^?0QN![X= MG)OTR*UV,FDO!U-NM(N,+J%]![ZBADIF4!&=SQD;A:T$%E+X BX>Q:+SC-!F MWM=$ZX2Y=4)P^AGBR37$OXXRQ^Y$ZSQ,.7_O!_EN- M33O"D(?)^]P8XEH-AO\!4$L#!!0 ( !"%C5FO[VJ!40@ (=D 4 M9VYW+3(P,3DP,3 Q7V1E9BYX;6S575UOX[@5?2_0_V"XSX[B9*?;!),N/)ZD M,'9FXL;9;MN7@)9HF0A%&B05V_^^I#X*5Y&W"2'E(;/F0//<Q?GYV/OW]V\+ M?XTC-"+,U.?C85[*U&(K-[ZZNO*23W-H!;E;"IJW<>GE= XUZT\#=2A0!'_R MT@^+4%)3=8&T)-0;]Y%*E&MD- 1YMTHAXW,H='X8G0Y/MO)8*B%'NB? M5&S!*7[ JX'Y^]O#[-!J2/D2,[R56R+PF<\CSR"\*=?&:KI)V;7 JYMAR+:Z MA?'5^?@\J?\O)8S:;[2_DD0;JL/T2FTCX>?-V\#%1H!(<\%-B)^2QM>Z"N'' M2SP*2(29Z8/#0=90,;Y#+80I3T.]#.-9*WA_WH?&1@&/$#F1=+6T \9)2Z,( M1TMC]TETRT7?GRNB]#2&28'WY\6XFIQ*+2_CM$_B%8JI^L.=,B]>YJP/$T;, M8/=-ORWQQCN%68"#G+FI\*2Q21%E2IRG/^/!:/"5^[$FI/3+%)EQR=E0[I $5+3)-FGS*P#>M]+.M'M'SM3C6,,]PQVU?')R+GG767EN=DVD>O?UIR_F[3HA.4/Z&^E30D_U_=RK]88TIUGWO7W6K/\M4T3M[PC%/V+@/IF&':,Z MK;>5+*BSHTPW)96G?DS]0!'0QVW('NAM(0QJ[BB?38E--7V!Z(P%>/) M?@3M@>HVQJ#LCG+:E-EFG!1;T%CC)? MB-WE:19<]M*"R_K'8(ZRX!*[J7YY+Q[Y%GCZ"(#[(_\19U!\IREPQBV)YE[, M!7\AZ6:')@>.2O3'!AMQT NG:7+>3]+I0INS($7V1_LB85!SIVER1FS.I4+T MOV33-#NUX?NC?Y4VZ(*CK#GK$>8V"K3LI 3IM-95IJ"\CE)C<\V9"(S@;EU$ M=%O<8Z*@MH[RW&^Z#CI?,[K7X#;= %1VGF M$;V9E#$6IWI1*=4G1^SD05\[\-6(AAE=TV)"=%ALD#&KN*--\'=C"5F-UV*>Q.FPQ5CO*-'-2Z4)E?=[= M+RD)$;PCJJ9 +]2'>(-&.,I/T_TJ,[;B(DI8W>D7=@NLT$Z+#S,&97>4GT[B M@"@R"_C3$HN].'I-FR\L.5 MRP05UZIO+]$#$VJ(@UXX?7@Z8PH+Y"OR@K\BA3*^=5[82_3 BQKBH!=.%QXG M)^I4QQ/R^K4#)6 /E*_R!05WNMYX$2%*O\12!R!KQY\2L >"5_F"@CM=47P; M81'J8? ?@F_5.MO(6">\M4 /#(!Y@T8X73E\NWO=6)UNK:MUH8+N@P5VTJ#^ MCG?*3GS?+#5)YP0L0 )P ,9WVH,&VJ +CM+D>[7&HC@K2ZB98.H6@C25ZK0C MK6H=MY?@/5 ZV.VH-1. M,]\OB#V+>*/\_5QP'V/S8$@>SLD6R5>K"GI@3_LX0./<;L5-OD(R^7+#Q1H) M+.]CE?QG!V-1('W3'\;=0R=SCXLG\P7S%I%F\\XIWZHAMZ MKI]<-1;OM%>G10%:5DB]/WM' >KFG_5GV7'SR_S+"WWD?U!+ P04 " 0 MA8U99U'1\)8* "8A0 % &=N=RTR,#$Y,#$P,5]L86(N>&ULS9U=;^.X M%8;O"_0_$.Y-"XSCB0,42##91<:3%,9FDVSLV6V[*!:TQ#A"9-*@Y,3^]R4E M499('DE)49)SD7'$]U OQ2CTY//(T1HQ.*$KB]' MWQ?CJ\5L/A^A+,C''_[\IR]I0E\NY(\5S@@2]=#L8I\EEZ/G M/-]>3"9O;V\G;VN690F'?J&DRRYR I[MRS">7$X>G>#0(7\;:QD8[EI M?#H=GYV>[+-X)(X>$O_*(\A92A[)$RJ:>9$?MN(09\EFFTI3Q;9G3I[L9E+. M)S)^0LD:YR26.SJ7.SK]N]S17ZK-MWA%TA&2RN^/<[!=YZVZJJ"):[,/A"[*_R#'/_X<&-..=-V')TL:M6; MRM&<<;/MF:BWJ#,CT;7* T9:,DXSM>$3>U2M-M]!1JAQM4J&02PU"Q]\7HQ\*#?I=J?[S97*L MQ4%'?V/1;D-HOA0U6EK0+G;5S393JI>;94%TLL60WL=*@J3&<0=?B1W'UHR9QWNL6D MT?<-35@(F,9@$AI:3P/[(UDGB/AE M)\[8"4\/O5 82M=< %9U-#194'38O8& U'*_C"PYIEDB![!>2$RI\],-P*QQ MZJ'I@N($, >?DM1ZOZ0LGDF:SMAFBVG_@&(3NZ8%-JSS8BJ#(@:T!S)31* J M)!QLKE_EZEPLDP8VMJ'W"8]ANXN?6APL0KK#@10584C&>2*I<1NBAR%#Z9H> MP*K.C28+BAB[-Y"54HX*O7](KFD\")%:YP<0S:8=CTH4(!QM9WUH"+5/,&Z2 M+,)IZ>5&;,LZFF?1N@8$M*M#8@B# @5R!\)2!BAFBA"OP/R+8#X,EX;2#RR& M53LJM2Q 4'1O?9A(O1=(9CO.6Z[A&0>6.KLIVV.VOC\+Z(( I<><<=>VE+= M\30#7=,\R0\W24KN=IL5X9;&F1)7;$#F%!-Z>1 L *9T!DH9DCI4"KWTO+I+ M0/,[O+&-$':96P+L)ML4M#4!D6 U!M!PU"(I]D+$3(Q,'*=S&I/]3^0 MLO0 MN64"L-F&0A,%1(7=&8!%)4:%&@FY%S >>++!_+!(HIZIPA2Z10,RVF9#5P4$ M!V -H*-2H\5\YG,F6>+]/!:@)D])^3QX#R6@WBTL/;;;S #B@-#I=@@0)()0 M.\HG2',:,;YEC<<=9FPG!L##C,7P"J4GRBU4@YK01JLS)"# AO@$,&N%?BJ? M24&,HZH")&OP0MQ5'(L#E57_W2:4G(+MMVK=TM5AM\V411@02; [@)]*^4E] M0#(&W=-0H)F^HZE3_]!,AT(S#1J:Z4>@6;ZQ0* Y>T=3S_Q#.W6 ?/_6"6,5Y'6O*17GO'XF2^1EEVB;M M0TRI"0^2MK'>P:54^T3B@64Y3O^=;#M/Q.UB+WA8#5LA:2G#0\5FKP^8,@:) M(!\GUA6N\H:&]54RK=S=*\ 66\=7@!N%04!@/2E%KKM9,LH)!D:$ M=K&S3K:8JONX419&%YN&C!XN_JZ%QL M1(\#IO1>+V2HT'FZ&B\S3&3VX;M1YFQFU^W4$[DJ"*)W=3?&-*W*'??F;SS) MQ9YG;+/9T>HNC^VY04#GJI<[;:H>MXJ"Z/TN9SH)E1:UQ8ZQ6+ TB9(\H>N? MQ.)$0$M$1Q4N ,K$0OW]Z MLL[V76)74/0;5G# RB @Z;6GPR("QE$C I4AJ(CQB\T\RW:$OPL>2X@GA$#S M $B&/D2<().]4)6!/ME:D&@GYL?#Z72U3/+4=G)I2IS-28"Y>D;2RH-@ S"E MLU"4(?:$3J=_7?T-J2C'W7_'EAS+I*J+PV;%4B#[E%7E"H(.BXH#BR0(%&!? M.@UW#%525&I]9*=JF;4T1RMW!8#5ENKZ5F$0G6YS9/SQM_K:TY!_O8^>A2D" MO)!@E[D>^FTF]>&_J0D"@0YCQDE))45*Z^.%A..4M>Y?!*R]+0+6/8N =8B+ M@/701<#:VR) [;9,$2+&I?M5FJPQD)RP4^T:B@[+.A\6:5"HP/[ ,:,.0<<8 MUQDMBQ1G<_K$^*;8_XWX8&DEH'.6T[++9IW4TB8*@I$N9T9:RS+I7$.,I-HU M%[LXR4EG1A\'0,),&3F68RF58!QY3 M7;J^E%X^@/$;2=.?*'NC"X(S1DE<7DNQW2GJUKM]8J;'=ONA&4 ;%N^3<-C(!.K?D #;;Q&BB@$BQ.P,(J<6H M5/MY0;O,'E$OLN2 9TT!TRUW_+IVIVGMK6VK-B!F.@U"[W!7.3^.:^,RRM,K MECF1WQ>1O))O.,>5-["]D-SU2Y5=IO6W*6W:@!#J- B^/UG'R%0Q6#'E+64, MGXFEUIIU/"6NJ=PGCC$LFKEC:DE >-A\=620X4AIO;"PV. T_;K+$DHR>"+2 M5&Y9L%ILL]"2!,2"S1? 0B%%2NN%A>L-X6LQO?V#L[?\NUJRO*,@( ),5U"*O$*("J67_O^*Z0O? M;?/H\,!91(A\RBJK1ZN^ZV\#H]TR\ZXFM6D:%!H09^_Q"Q!XK (UZOC4F+%\ M7LR3#XW+;&XL>ED\8W$ [W=Y)F=080R^"MX9Y/CVPH &:#<9.B("0F^ 3>B& M0Q&)BM!/J Q&C6A/YV?9,0L@B;\>'LD3X?*]@R79YU_%CEXZSC &Q+H^>QO< M'/UDKC&ULS9S1[ A; M&$UDB9'L &]?R086@R0?;GR2BX287_;YOV/+/K;D]Q_6*6^]4J69%#?MWL5E MNT5%)&,FDIMVKCM$1XRU6SHC(B9<"GK3%K+]X?=[NKU>IB-;B0*NGV+R][W7\^/TRB!4U)APF[OHBV=ZWL6ESM M>E=75]WBVYWT1+F>*;[;QJ"["V>_9O,M"^@/(M'L6A?A/LG__>A[OMYIP.:."KO2**7H1 MR;1K%=VA--DRX19M%XK.;]J)6)DM]*XN>Y?%^G^J:++-TB1-LW3)C9NU512ZJ8*L-ZMRZBHDJ^ M3O?0K:*[),JLJ!,M&-^G>JYDZJ.S)2$]@1Z",IMHAN:MV7YL8QAQDKAQ'DF M/'L80)UNL(A^I#I2;&FYU("M*(%\^ZA\'=X:QKP[=IYIPFR\-I2)H43MPG"_ MX&D"!#_ ["F";I$R<"M$3O@S74I5 [ZJ!/+^&9.WRQL2YC]SHC*J^ 9"^D0, MA/T+)FR/0R3>4T6$9I8/!/BI&DC\5]0+#X]').23!>5\*-,E$:"]W*4'8G^' MB=WO\PV OW^UYW=S:H&S/V@"Q/_;6\%_XA8I T]4,1F;4[H"L#\1 ZE?85+W M.$3E?2]B*.V]%%S_X,,^LH>$>L1T1'@9T<@LTV'<#CD4.4K-66L3%?N_E"@P M] ,Q%#E*&5ICL6'@PURI2C#!7L6OAB)'*4#K3#;,_%YD+-N,&*=?\G3V_<9I ME?6I"LH8I>CTF4)AN[O3(+(O)/7LRVXEE#%*K1DRA\)Y:/PHPL6""]D*I<,K!SXCP$A"P^4:P]\_#WH=C1ZE#:VV^$>R#\[ /X-A1:M%: MFYC8A^;CHYK*E><)M%<,18Y2B]98Q 1>G&D>U9.2KZP<'%5'_:0%%#UBB1HV MB[K#ER=YR-Z^4T)Y(Y:K;G.8G)^DS@C_CRWKKB3=>BASQ,(U9+3I&XQEWNU- M"]]0HB,)E"]*K>JTTS12FV%%B7_WK2J@0%$*4)>9AGD^2/OL8R%%\'[LJ0K* M%:62])EJNN.UHXFU]] _^!H\@@VE6SVVT3#&KXIE)H*A3--<;._1>)Z*>:10 MO"CE7]!>PZ@GDK.(94PDG\T5HF*$NSF[=%#(*,6>WUC#A)\4M9FFYK*[&,=E MIQNHQ_GO5%<\F.M]H!3^Z2%.(90P2H$7L-8PY$H< M;KQ'$BA8E,K.:0>I3[A?1PLB$NH?O>!60@&C5'HAY,S^UZ4BL]G M"HEM.3;<'%&/,\X2XI])%FP GF>#23Q@M>GY>\64G[&82Y46<8S,!S=VCQ0* M'&>*9,A>TZCSF&4T+D,:,4%$9$JJ_;PV3W5>WPJ: )PYE$#3*+?WOU+./PFY M$A-*M!0T+B_U0W?XO4V@64!\AEAC%R4%?TN>&TJJ& BJ/,> 1PI%COCLT&,/ M9^QE.:AY?^ZQ!Z%OI'RX!10\XD/$L%FD\6D9M3&S5_J19&0;88B_KP64/^(# MQ;!9M/'S:FA./(D,/S,_$D)I(PZ%=5I#@3Q)">=WN6:"ZF#?B(6IRQC.G*E\QEDTXI($K\LK,BA?Q"K4 M80L%[QT1+RI?9M'F2E9*'!N%\@TM9.)9/0R M61C3^C'/BM=[FOB"-PV"[:"IP9S$"3".=!6DOT_THO'=YIG.J;+#%*9TG=V9 M#;V$+XH S:'Y07VC$!B#(TWONR>^'LP"^Z+:\AO[R[Z,U2SY'U!+ 0(4 Q0 M ( !"%C5FMFH9'+A< +FT + " 0 !E>&A?.3DQ M+FAT;5!+ 0(4 Q0 ( !"%C5F9T)=TP@T !$[ . " M 5<7 !F.&M?,3(Q,S(T+FAT;5!+ 0(4 Q0 ( !"%C5F%)5>KL ( -4+ M 0 " 44E !G;G'-D4$L! A0#% M @ $(6-6:_O:H%1" AV0 !0 ( !(R@ &=N=RTR,#$Y M,#$P,5]D968N>&UL4$L! A0#% @ $(6-66=1T?"6"@ F(4 !0 M ( !IC &=N=RTR,#$Y,#$P,5]L86(N>&UL4$L! A0#% @ M$(6-66S!0-7W!@ ]E8 !0 ( !;CL &=N=RTR,#$Y,#$P ?,5]P&UL4$L%!@ & 8 >0$ )=" $! end XML 18 f8k_121324_htm.xml IDEA: XBRL DOCUMENT 0001540159 2024-12-13 2024-12-13 iso4217:USD shares iso4217:USD shares 0001540159 false 8-K 2024-12-13 EDESA BIOTECH, INC. A1 001-37619 100 Spy Court Markham ON L3R 5H6 289 800-9600 false false false false Common Shares EDSA NASDAQ false